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  In the last decades, honeybees have been afflicted by several gut diseases such as 
the American Foulbrood (caused by Paenibacillus larvae), the European Foulbrood 
(Melissococcus plutonius) and Nosemosis (Nosema ceranae). The virulence of these 
diseases is enhanced by synergy with abiotic stressors such as climate change, causing 
noteworthy losses in honeybee colonies and consequitively honey production. 
  To counteract losses, pharmaceutical companies have developed specific medications 
against microbial mediated honeybee diseases. Antibiotics and chemotherapeutics, such 
as tetracycline, tylosin or sulfonamides, are diffused worldwide among beekeepers. 
After the ban of antibiotics at a European level in 2001, researchers and pharmaceutical 
companies alike have made a strong effort to find alternative medications. Consequently, 
several new medications based on natural oils with proven strong antimicrobial activity 
such as thymol, Neem oil and probiotics have been brought forward on the veterinary 
market, or suggested by researchers as future ‘natural’ alternatives. However, the use of 
oral medications on animals may effect honeybees’ gut microbial community. 
  In this work, we investigated if and how traditional chemotherapeutic strategies and 
new approaches, based on the use of oils and probiotics, can change the honeybee gut 
microbial community. A field and laboratory trial was carried out using eight assays 
based on the use of thymol, neem oil, probiotics, tylosin, tetracycline, sulfaquinoxaline, 
tween80 and a control with no treatment. Six micro hives for each assays (for a total 
of 48 micro hives) were establishes near Bologna and each hive was treated once a 
week for three weeks according to the instructions of the veterinary medication 
manufacturers. Four weeks after the beginning of the test, ten bees were sampled 
from each micro hive. Microbial gut DNA was extracted, amplified and sequenced 
on the MiSeq Illumina platform. Preliminary data shows important changes in the gut 
microbiota community of honeybees, with thymol and tetracycline identified as the 
main therapeutic ingredients responsible for shaping the microbial community.
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